Skip directly to content

Pfizer Partners with Halodoc, YKI to Launch Digital Patient Assistance Program for Breast Cancer Patients

20/05/20

19 May 2020, Jakarta: Pfizer Indonesia has today announced, a partnership with healthcare platform Halodoc and Indonesia Cancer Foundation (YKI) to launch an innovative digital solution for metastatic breast cancer patients.

Known as ASA DARA, it is a unique, digitally-enabled patient assistance program introduced by Pfizer to help breast cancer patients in Indonesia gain convenient access to their required therapy.

ASA DARA offers a seamless service to patients via a digital platform managed by Halodoc with YKI. Through this program, after patients consult with their oncologists/specialist doctors and get prescriptions for Pfizer medicines, they will have an opportunity to get assistance and delivery services for their therapy at their doorstep whilst enhancing their affordability and medication adherence levels.

Anil Argilla, President Director - PT Pfizer Indonesia, said, “Pfizer uses innovative patient service approaches, including patient assistance programs to help support patient get the medicines they need in line with our goal to bring breakthroughs that change patients’ lives. We began to explore this partnership idea late last year and this program is becoming relevant today as we live in a new environment with restricted mobility due to the global threats of COVID-19 pandemic. Our partnership with YKI and Halodoc reflects our continued commitment to the patients and support the broader Indonesian healthcare system to provide innovative healthcare solutions through digital technology.”

Breast cancer is one of the most common forms of cancer in the world.1 The disease ranks first in reported cancer cases in Indonesia with 58,256 new cases in 2018 and ranks second in death cause of cancer with 22,692 cases after lung cancer, according to a 2018 study by Globocan.2 Worldwide, breast cancer is the most common invasive cancer in women, with more than 2 million women impacted annually.3

Jonathan Sudharta, CEO of Halodoc, stated, “The partnership brings unique value for breast cancer patients and it will further strengthen the digital health ecosystem in Indonesia. We hope the shared value created from this cooperation will help to address the challenges that Indonesian patients face in terms of accessing innovative therapies, by providing them a simpler and more convenient service.”

“YKI supports the ASA DARA patient assistance program as it is a novel and innovative breakthrough in facilitating wider access to breast cancer patients across Indonesia to get their required medicine,” remarked YKI Chairperson Prof. Dr. dr. Aru Sudoyo, SpPD, KHOM, FINASIM, FACP.

“Our role is to ensure that only patients that are recommended by their oncologists and meet ASA DARA’s administrative requirements are eligible for this program,” added Prof. Sudoyo. The required documents consist of patient’s ID card, prescription with valid oncologist’s stamp, and filled ASA DARA form to be submitted to Halodoc, which will be verified by YKI.

Pfizer recognizes there is still more work to be done to provide comprehensive and credible information to people living with breast cancer, including those with metastatic HR+ and HER 2- disease. 

“The next journey of our partnership is to expand this program with patient education programs to benefit the broader patient community in Indonesia. Together, we can enhance patient awareness on cancer management concepts and at the same time tackle misinformation regarding cancer treatments,” added Anil.

###

Notes to the editor:

HR+, HER2- DISEASE:

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) disease is the most common subtype of breast cancer, representing about 73% of all cases, followed by HER2+ and then triple negative breast cancer.4,5,6,7 

About Pfizer: Breakthroughs that Change Patient Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.

In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

About Halodoc

Halodoc an integrated health service application that provides comprehensive and reliable healthcare solutions that simplify access to healthcare. The app has four multiple features that assist patients to obtain their therapy conveniently. For instance, Buy Medicines, a service that helps its users buy supplement, vitamins and medicines fast, convenient, safe and secure because the products are delivered to the users’ homes. A patient can also upload their recipe onto the application. Visit a Hospital, which helps doctors make medical appointment from their HP, so when they arrive at the hospital, they don’t need to complete all the administrative requirements and they can consult their doctor without queuing. Halodoc partners with Prodia in facilitating access to health checks at home or at the office. In 2018, Halodoc won “The Most Innovative Start Up” from Galen Growth Asia and was voted by Forbes Indonesia as “Choice Start Up”. In 2019, Halodoc was voted “Startup Chosen by Tempo 2019” in People’s Choice category.

About Indonesia Cancer Foundation

Indonesia Cancer Foundation (YKI) is a non-profit, social organization established to tackle the growing disease burden of cancer and the lack of knowledge amongst the Indonesian communities regarding the healthy lifestyle to avoid risks of cancer and to conduct early detection efforts. As a result, cancer cases reach advanced stage and are becoming difficult to tackle, resulting in increased burden to the patients and their families.

YKI was founded by 17 community leaders and concerned healthcare providers on 17 April 1977 and their mission is to enhance public knowledge and to address the growing death cases from cancer as well as well to respond to patient needs who are detected at the advanced stage.  

Pfizer Indonesia website: www.Pfizer.co.id

 

Reference:

[1] World Health Organization. Projections of mortality and causes of death 2015 and 2030. http://www.who.int/healthinfo/global_burden_disease/projections/en/. Updated July 2013. Accessed May 12, 2020.
2 Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. [cited 28 February 2020] Available from: http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
3 World Health Organization. Cancer. Breast Cancer. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accessed May 12, 2020
4 Yersal O and Barutca S. “Biological subtypes of breast cancer: prognostic and therapeutic implications.” World J Clin Oncol. 5.3 2014; 412–424. PMC.
5 Esserman LJ and Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. Up-to-Date. (Burstein H, Vora SR, eds). 2017
6 Boyle P. et al. Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of Oncology. 2012;6,1:vi7–vi12.
7 Kohler et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. JNCI J National Cancer Inst. 2015: 107(6):1-25.